Illumina (ILMN) has entered a multiyear partnership with Ovation.io to develop a dataset with integrated clinical multiomic insights from 25,000 patients treated with glucagon-like peptide-1 therapies, the companies said Thursday.
The commercially available dataset is expected to help the pharmaceutical industry advance drug discovery and development, the companies said.
Under the agreement, Ovation.io will supply genome samples from its biobank, which will be sequenced by Illumina, they said.
The initial phase of the collaboration prioritized developing datasets from patients with liver and chronic kidney disease, as well as those treated with GLP-1 receptor agonists. The companies intend to scale the GLP-1 dataset moving forward.
Price: 77.84, Change: +0.24, Percent Change: +0.31
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。